Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
78 Cards in this Set
- Front
- Back
Cerebral Toxicity and acral erythema are possible side/adverse effects of |
Cytarabine |
|
# of new cases of leukemia diagnosed annually in 2014 |
52380 |
|
Treatment option for CD 33+ AML first relapse |
Gemtuzumab |
|
Initial treatment of APL |
ATRA (all-trans retinoic acid) |
|
Treatment of AML |
Cytosine arabinoside |
|
Main treatment of NHL (biologic) |
Rituximab |
|
This kind of leukemia has three distinct phases |
CML |
|
Chronic phase, accelerated phase, and blast crisis are three phrases of this type of leukemia |
CML |
|
In ALL, the _____ is the sanctuary for leukemic cell |
CNS |
|
Intrathecal chemo &/or high dose systemic chemo & cranial radiation are used as treatment/prophylaxis for ________ in ALL |
CNS involvement |
|
Graft vs. host disease plays an intended effect for this kind of treatment in leukemia. |
Nonmyeloablative transplant. |
|
95% of CML patients has positive test for this kind of chromasone. |
Positive Philadelphia chromasone |
|
These two sites are the sanctuary sites for ALL |
CNS and testes |
|
Induction therapy for AML includes |
Cytarabine + anthracycline |
|
Diagnostic procedure for AML |
Bone marrow biopsy and aspirate with special stain => + Auer rods |
|
The staging system used for Chronic Lymphocytic Leukemia |
Rai and Binet |
|
The staging system used for Acute Leukemia |
French American British (FAB) |
|
What are the blood-forming organs? |
Bone marrow, liver, and spleen. |
|
B and T lymphocytes are part of __________ stem cell |
Lymphoid |
|
White blood cells, RBC's, and platelets are parts of ___________ stem cell. |
Myeloid. |
|
T/F:
Leukemia cells are capable of infiltrating and accumulating in other organs (e.g. CNS, eyes, testes, skin) |
True |
|
Organ involvement is most common in this type of leukemia: __________. |
Acute Leukemia. |
|
These abnormal labs are usually associated with this type of leukemia:
* WBC: myeloblasts, Low/normal/high, & neutropenia (ANC< 1000 cells/mm^3) * Low platelet * Low RBC * Other: hyperuricemia, elevated LDH. |
AML |
|
These abnormal labs are usually associated with this type of leukemia:
* WBC: Lymphoblasts, low/normal/high, Neutropenia (ANC <1000 cells/mm^3)
* Low Platelet
* Low RBC
|
ALL |
|
These abnormal labs are usually associated with this type of leukemia:
* Mature meylocytes (>100,000 cells/mm^2) * Normal or high platelet * Low RBC * Other: High serum B12 level, Low LAP level |
CML |
|
These abnormal labs are usually associated with this type of leukemia:
* WBC: small mature or immature lymphocytes, B cells, >20,000 cells/mm^3 in early disease, > 100,000 cells/mm^3 in advanced disease
* Low platelet * Low RBC |
CLL |
|
Lymphadenopathy occurs with these two types of leukemia |
ALL & CLL |
|
Splenomegaly occurs with these types of leukemia |
ALL, CML, & CLL |
|
Hepatomegaly occurs with these types of leukemia |
AML, CML, & CLL |
|
This kind of leukemia has the same signs as AML plus lymphadenopathy and splenomegaly. |
ALL |
|
Peripheral blood leukocytosis is one of the signs of __________ leukemia |
CML |
|
Hypogammaglobulinemia & rashes are signs (of all signs) of this kind of leukemia |
CLL |
|
The most common forms of leukemia in adults are... |
AML and CLL |
|
This kind of type of chemotherapy is considered a risk factor for leukemia: ___________ ____________. |
Alkylating agents |
|
drug tx for relapsed/refractory APL (previously treated with ATRA & athracycline-based) |
Aresenic Trioxide |
|
Please choose the correct answer
Treatment for CNS leukemia includes:
A. Intrathecal cytarabine B. Intrathecal methotrexate C. IV methotrexate D. IV cytarabine E. A & C F. A & B |
Correct Answer:
F. Intrathecal cytarabine and intrathecal methotrexate are used for CNS
IV is not effective for CNS invovlement. |
|
For AML:
Post remission therapy to reduce leukemic cell population and achieve long-term, disease-free survival (DFS) includes: ..... |
1. Consolidation 2. Intensification 3. Maintenance 4. Bone marrow transplantation. |
|
For acute myeloid leukemia: What is....
"one or two cycles of the same chemotherapy agents used in the induction therapy. Usually given after remission occurs" |
Consolidation therapy |
|
For acute myeloid leukemia: What is...
"High-dose chemotherapy given immediately or within several months of induction therapy. Same chemotherapy agents may be used at higher doses, or different drugs thought to be cross resistant with induction therapy drugs may be used." |
Intensification therapy |
|
For AML: What is...
Lower doses of the same drugs used for induction therapy or different drugs given monthly for a prolonged time period to 'maintain' a disease-free state. This therapy not currently recommended in treatment of AML." |
Maintenance therapy |
|
For AML:
This drug is used to treat clients 60 y.o. or older in first relapse with CD33+ AML and who are not candidates for cytotoxic chemotherapy. |
Gemtuzumab ozogamicin |
|
For AML:
___________ may be offered to clients who are elderly or clients with high-risk factors causing them to be ineligible for myeloablative transplantation. |
Nonmyeloablative transplantation |
|
For acute leukemia:
This therapy has graft-versus-host disease with graft-versus-tumor effect as intended to eradicate disease |
Nonmyeloablative transplantation |
|
Cell morphology, age, WBC count at presentation, success of initial induction therapy, chromosomal abnormalities are prognostic factors of _____________ ___________ leukemia. |
Acute lymphocytic leukemia (ALL) |
|
Initial treatment of ______________ includes: Vincristine, Prednisone, anthracycline, cyclophosphamide, with or without asparaginase. |
ALL |
|
Post-remission therapy for _________ includes short-term, relatively intensive chemotherapy followed by longer-term therapy at lower doses. Multiple drugs not previously administered may be given. |
ALL |
|
When to use the following treatment for ALL:
Allogeneic BMT from histocompatible leukocyte sibling human leukocyte antigen (HLA) donor |
For clients younger than age 50 in first CR with high-risk ALL. |
|
The two agents that are used for chronic phase CML to control leukocytosis (but do not eradicate disease or induce cytogenetic remission) include: 1. ___________________ & 2. _____________________
The other agent that is used for chronic phase include: 3. ____________________________ |
1. Hydroxyrea 2. Busulfan (Myleran) 3. Alpha-2a interferon |
|
During blastic crisis for CML, ______ _______ is used for lytic bone lesions. |
Radiation Therapy (RT). |
|
____________ can be used during blastic crisis in CML for palliation. |
Hydroxuria |
|
After alpha-2a interferon failure, what medication is approved for treating CML (chronic phase, accelerated phase, or blast crisis) |
Imatinib mesylate (Gleevec) |
|
T/F
Client who is asymptomatic in CLL should be treated ASAP. |
False
Rationale: Treatment should be delayed until patient is symptomatic, e.g. exhibiting signs of hemolytic anemia, cytopenia, lymphadenopathy that is painful and/or disfiguring, or symptomatic organomegaly. |
|
The lab value is used to monitor CLL |
Lymphocyte count |
|
In CLL:
_________ chemo is used to suppress production of well-differentiated, small lymphocytes |
Chlorambucil (Leukeran) |
|
In CLL:
This chemo is used to inhibit growth of less mature lymphocytes (with limited effect on neutrophils and platelets). |
Cyclophosphamide |
|
In CLL:
What drug can be used to control leukocytosis and immune-mediated cytopenias? |
Corticosteroids. |
|
In CLL:
What procedure can be used to relieve symptom of leukocytosis and immune-mediated cytopenias when steroids are no longer effective? |
Splenectomy |
|
In CLL:
What's an effective treatment for painful lymphadenopathy and/or splenomegaly? |
Radiation Therapy (RT) |
|
What's the approved treatment for B-Cell CLL? |
Fludarabine (Fludara) |
|
In CLL:
Treatment for CD+ lymphocytes |
Rituximab and alemtuzumab (Campath-1H) |
|
10% of patients never require treatment for this kind of leukemia |
Hairy Cell Leukemia |
|
When to treat hairy cell leukemia? |
* When cytopenias is symtomatic * When there's massive splenomegaly * or when there're other complications. |
|
The following are treatment options for ______________:
1. 2-Chlorodeoxyadenosine (2-CdA) 2. Pentostatin (Nipent) 3. Alpha-interferon 4. Splenectomy |
Hairy Cell Leukemia |
|
When is splenectomy indicated in Hair Cell Leukemia? |
When client has low WBC count, splenomegaly, and minimal bone marrow involvement. |
|
Name the two viruses that are associated with leukemia (risk factors for leukemia) |
1. HIV 2. Epstein-Barr virus |
|
What previous chemo agents are known to be risk factors for leukemia? |
1. Alkylating agents 2. Etoposide |
|
What medications previously used by patients identified as risk factors for leukemia? |
1. Chloramphenicol (antibiotic) 2. Phenylbutazone (NSAID for animals) |
|
What genetic abnormalities are known to be risk factors for leukemia? |
1. Down syndrome 2. Turner's Syndrome 3. Bloom's Syndrome 4. Klinefelter's Syndrome 5. Fanconi's anemia 6. Neurofibromatosis 7. Ataxia telangiectasia |
|
What abnormal values of cerebrospinal studies would be associated with leukemia? |
1. Increased protein 2. Decreased glucose 3. Leukemic cells presence |
|
What are the most common sites of leukostasis? |
1. Brain/CNS 2. Lung 3. Other organs may be involved |
|
What clients are at risk for leukostasis? |
Clients that have diagnosis of cute or chronic leukemia with a WBC count > 50,000 to 100,000/mm^3. |
|
Describe the physiologic effect of leukostasis |
Increase in blood viscosity => obstruction of the microcirculation or formation of thrombi of WBC's in small vessels => capillary plugging, vessel rupture, bleeding, and organ damage. |
|
What are the most common signs of leukstasis? |
1. Increased ICP 2. Respiratory distress 3. Other signs depend on organ(s) involved |
|
What are the most common complications of leukostasis? |
1. Pulmonary hemorrhage 2. Cerebral hemorrhage |
|
Please describe the medical management for leukostasis in leukemia |
1. Initiation of chemotherapy to treat the disease process 2. Initiation of leukapheresis to temporarily decrease the WBC count 3. IV fluids 4. Cranial radiation if appropriate
|
|
Please describe the nursing interventions for leukostasis |
Frequency of monitoring depends on each patient and s/s. General guidelines are followed: 1. If WBC >50,000 - 100,000/mm^3 - Neurologic exam q2-4 hr 2. VS monitoring q 2-4 h 3. Monitor for s/s of bleeding q2-4 hr 4. Management of myelosuppression 5. Contact physicians for aberrant findings. |
|
Retinoic acid syndrome (RAS) is a potentially life-threatening complication that can be observed in patients with ________ leukemia. |
APL (acute promyolytic leukemia). |
|
S/S of RAS (retinoic acid syndrome) |
Fever, dyspnea, weight gain, hypotension, pulmonary infiltrates |